<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;
mso-fareast-language:EN-US;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
span.EmailStyle20
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:windowtext;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link="#0563C1" vlink="#954F72"><div class=WordSection1><p class=MsoNormal>Hi all:<o:p></o:p></p><p class=MsoNormal>Please see below for a survey relating to drug funding for prostate cancer.<o:p></o:p></p><p class=MsoNormal>Note there is a 1 day deadline for participating.<o:p></o:p></p><p class=MsoNormal>I just got it today.<o:p></o:p></p><p class=MsoNormal>Thx.<o:p></o:p></p><p class=MsoNormal>Glen<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><div><div style='border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='mso-fareast-language:EN-CA'>From:</span></b><span lang=EN-US style='mso-fareast-language:EN-CA'> john baxter <br><b>Sent:</b> March 4, 2020 1:38 PM<br><b>To:</b> Glen Tolhurst <glen46nor@gmail.com><br><b>Subject:</b> Fwd: Patient Input for Drug Funding<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal style='margin-bottom:12.0pt'><span style='mso-fareast-language:EN-CA'><o:p> </o:p></span></p><div><p class=MsoNormal>Kind Regards,<o:p></o:p></p><div><p class=MsoNormal>John<o:p></o:p></p></div></div><div><p class=MsoNormal style='margin-bottom:12.0pt'><br>Begin forwarded message:<o:p></o:p></p></div><blockquote style='margin-top:5.0pt;margin-bottom:5.0pt'><div><p class=MsoNormal style='margin-bottom:12.0pt'><b>From:</b> Anne Breakey Hart <<a href="mailto:anne.breakeyhart@cancer.ca">anne.breakeyhart@cancer.ca</a>><br><b>Date:</b> March 2, 2020 at 11:28:51 PM EST<br><b>To:</b> Anne Breakey Hart <<a href="mailto:anne.breakeyhart@prostatecancer.ca">anne.breakeyhart@prostatecancer.ca</a>><br><b>Subject:</b> <b>Patient Input for Drug Funding</b><o:p></o:p></p></div></blockquote><blockquote style='margin-top:5.0pt;margin-bottom:5.0pt'><div><p class=MsoNormal> <span style='mso-fareast-language:EN-CA'><o:p></o:p></span></p><p class=MsoNormal>Hi Everyone,<o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal>We would like to hear from prostate cancer patients, survivors, caregivers, and supporters like yourself and your group members. As we have in the past, we are continuing to work with the pan-Canadian Oncology Drug Review (pCODR) regarding patient input for drug funding recommendations.<o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal>pCODR has a new survey out and we invite the PCCN groups to participate if they can. Please complete <a href="https://form.simplesurvey.com/f/s.aspx?s=8ef2b91e-61ed-4682-8aea-22c016ab334a&lang=EN">this survey</a> and share your thoughts by Thursday, March 5. <b>(I realize that this is very short notice)</b><o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal>We are particularly interested in hearing from people who have taken enzalutamide (Xtandi) to treat metastatic castration sensitive prostate cancer.<o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal>As well you can contact Paulysha De Gannes, Policy Analyst at the Canadian Cancer Society, (who has worked at PCC with us and on Stuart’s team). if you have any questions please email her at <a href="mailto:Paulysha.degannes@cancer.ca">Paulysha.degannes@cancer.ca</a> <o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal>Thanks so much,<o:p></o:p></p><p class=MsoNormal>Anne<o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal><span style='color:#1F497D'> </span><o:p></o:p></p><p class=MsoNormal><span style='color:#1F497D;mso-fareast-language:EN-CA'> </span><o:p></o:p></p><table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=640 style='width:480.0pt;border-collapse:collapse'><tr style='page-break-inside:avoid;height:45.9pt;mso-height-rule:exactly'><td width=54 valign=top style='width:40.5pt;padding:0cm 0cm 0cm 0cm;height:45.9pt;mso-height-rule:exactly'><p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%;text-autospace:ideograph-other'><b><span style='font-size:9.0pt;line-height:115%;font-family:"Verdana",sans-serif;color:#0066CC;mso-fareast-language:EN-CA'><img border=0 width=42 height=42 style='width:.4375in;height:.4375in' id="Picture_x0020_1" src="cid:image001.png@01D5F0D0.B998F290" alt="cid:image003.png@01D5D6CB.F1BC91F0"></span></b><o:p></o:p></p></td><td width=586 valign=top style='width:439.2pt;padding:0cm 0cm 0cm 0cm;height:45.9pt;mso-height-rule:exactly'><p class=MsoNormal style='margin-bottom:10.0pt;line-height:115%;text-autospace:ideograph-other'><b><span lang=EN-US style='font-size:9.0pt;line-height:115%;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'>Anne Breakey Hart<br></span></b><span lang=EN-US style='font-size:9.0pt;line-height:115%;font-family:"Verdana",sans-serif;color:#333333;mso-fareast-language:EN-CA'>Manager, Volunteer Engagement and PCCN</span><b><span lang=EN-US style='font-size:9.0pt;line-height:115%;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'><br>Canadian Cancer Society, National</span></b><o:p></o:p></p></td></tr></table><p class=MsoNormal><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:black;mso-fareast-language:EN-CA'>Email</span></b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'> <a href="mailto:anne.breakeyhart@cancer.ca">anne.breakeyhart@cancer.ca</a><span style='color:#333333'><br></span><b>Tel</b> <span style='color:#333333'> 416-441-2131 x229<br>55 St Clair Avenue West, Suite 300<br>Toronto, Ontario M4V 2Y7</span></span><o:p></o:p></p><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:#333333;mso-fareast-language:EN-CA'> </span><o:p></o:p></p><p class=MsoNormal><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:#333333;mso-fareast-language:EN-CA'>Connect with us online</span><o:p></o:p></p><p class=MsoNormal><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:blue;mso-fareast-language:EN-CA'><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__Cancer.ca&d=DwQGAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=VV1LUpyMlajFjRGD3IhqBP9DSk_y9eZQ7i6s0l6uNiwQmJ6WdWEFdN9hXQY-T8Hc&m=Q1o4OSn6JJge7BlNwRAVijs2xckQ7Hl9EuTEuEVWVjA&s=0Ngez5MvaSQwuOYrz9E-R09mW9sGQfkM98AUVvuNwuE&e="><span style='color:blue'>Cancer.ca</span></a></span></b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'> | </span><span style='mso-fareast-language:EN-CA'><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.facebook.com_CanadianCancerSociety&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lD73s9PycfBzhn7YizEEmnLB61jKB_FgJ4a0KrFuLao&m=iEgx-EcxBiw4ljFhsCmUsP0B3po_CKNNR51WpOvKWNc&s=x7sAOn4uNtrVaYGajcRoJZwZqP9rhm6HXTyNzB5V3jw&e="><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:blue'>Facebook</span></b></a></span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'> | </span><span style='mso-fareast-language:EN-CA'><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__twitter.com_cancersociety&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lD73s9PycfBzhn7YizEEmnLB61jKB_FgJ4a0KrFuLao&m=iEgx-EcxBiw4ljFhsCmUsP0B3po_CKNNR51WpOvKWNc&s=SYmoeOydyX7WjQ_hEj9pJQu22DAaTbQmPkrfiQ3f3bg&e="><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:blue'>Twitter</span></b></a></span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'> | </span><span style='mso-fareast-language:EN-CA'><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.youtube.com_user_CDNCancerSociety&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lD73s9PycfBzhn7YizEEmnLB61jKB_FgJ4a0KrFuLao&m=iEgx-EcxBiw4ljFhsCmUsP0B3po_CKNNR51WpOvKWNc&s=ZIIjmuvpZ6_l2XP05dC-b5Y-JrIwkZdzt7UcvCBtkD0&e="><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:blue'>YouTube</span></b></a> </span><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:#0063B3;mso-fareast-language:EN-CA'>| </span><b><span style='mso-fareast-language:EN-CA'><a href="https://www.prostatecancer.ca/"><span style='color:blue'>Prostatecancer.ca</span></a></span></b><o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal><span style='mso-fareast-language:EN-CA'> </span><o:p></o:p></p><p class=MsoNormal><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'> </span></b><o:p></o:p></p><p class=MsoNormal><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'>On February 1, Prostate Cancer Canada and the Canadian Cancer Society amalgamated. </span></b><span style='mso-fareast-language:EN-CA'><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.cancer.ca_en_about-2Dus_for-2Dmedia_media-2Dreleases_national_2020_ccs-2Dpcc-2Damalgamation_-3Fregion-3Don&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=lD73s9PycfBzhn7YizEEmnLB61jKB_FgJ4a0KrFuLao&m=iEgx-EcxBiw4ljFhsCmUsP0B3po_CKNNR51WpOvKWNc&s=cFb-zyF7iSCjwyr-gyCR6cUyeNNPM0MZ6-E3wurG0mM&e="><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;color:blue'>Learn more</span></b></a></span><b><span style='font-size:9.0pt;font-family:"Verdana",sans-serif;mso-fareast-language:EN-CA'>. Together, we are a force-for-life in the face of cancer. </span></b><o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal><span style='color:#1F497D;mso-fareast-language:EN-CA'> </span><o:p></o:p></p><p class=MsoNormal><span style='color:#1F497D;mso-fareast-language:EN-CA'> </span><o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p><p class=MsoNormal><span lang=FR-CA style='color:#1F497D;mso-fareast-language:EN-CA'> </span><o:p></o:p></p><p class=MsoNormal><span lang=FR-CA> </span><o:p></o:p></p><p class=MsoNormal> <o:p></o:p></p></div></blockquote></div></body></html>